Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
98.70
+2.03 (2.09%)
Jul 11, 2025, 4:00 PM EDT
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B EUR
Revenue Growth
-2.42%
P/S Ratio
2.42
Revenue / Employee
544.97K EUR
Employees
82,878
Market Cap
118.29B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Elite Pharmaceuticals | 84.04M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Sanofi News
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 2 days ago - Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony - Benzinga
- 4 days ago - Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug - Benzinga
- 5 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 12 days ago - Adagene gains as Sanofi collaboration expands - Seeking Alpha
- 13 days ago - Press release: Availability of the Q2 2025 Aide mémoire - GlobeNewsWire
- 13 days ago - Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy - GlobeNewsWire
- 16 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire